| Relugolix studied in …STUDIED_INderived35 of 35show fewer |
|---|
| → studied in | NCT07025369Phase 2 · recruiting Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial · 35 trials list this drug (17 active) | — | — | Prostate Adenocarcinoma,Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06111781Phase 2 · recruiting The SUGAR Study; SBRT and Relugolix) for Prostate Cancer · 35 trials list this drug (17 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04423211Phase 3 · recruiting Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging · 35 trials list this drug (17 active) | — | — | Prostate Adenocarcinoma,Malignant Prostate Neoplasm,Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04513717Phase 3 · active not recruiting Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial · 35 trials list this drug (17 active) | — | — | Prostate Adenocarcinoma,Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05050084Phase 3 · active not recruiting Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial · 35 trials list this drug (17 active) | — | — | Prostate Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05053152Phase 2 · active not recruiting Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study · 35 trials list this drug (17 active) | — | — | Prostate Adenocarcinoma,Prostate Intraductal Carcinoma,Malignant Prostate Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07455903Phase 2 · recruiting Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT · 35 trials list this drug (17 active) | — | — | Malignant Prostate Neoplasm,Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05765500Phase 2 · recruiting RecoverPC: Relugolix vs GnRH Agonist in Quality of Life · 35 trials list this drug (17 active) | — | — | Prostate Neoplasm,Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06378866Phase 2 · recruiting Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial · 35 trials list this drug (17 active) | — | — | Malignant Prostate Neoplasm,Castration-Resistant Prostate Carcinoma,Castration-Sensitive Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05467176completed A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX · 35 trials list this drug (17 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05605964Phase 3 · completed Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate · 35 trials list this drug (17 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06499870Phase 2 · recruiting Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial · 35 trials list this drug (17 active) | — | — | Prostate Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04523207Phase 2 · completed A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases · 35 trials list this drug (17 active) | — | — | Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06330805Phase 2 · recruiting Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer · 35 trials list this drug (17 active) | — | — | Prostate Adenocarcinoma,Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06463457Phase 2 · active not recruiting Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED) · 35 trials list this drug (17 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06650579Phase 3 · recruiting REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial · 35 trials list this drug (17 active) | — | — | Malignant Prostate Neoplasm,Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05320406Phase 2 · active not recruiting RElugolix VErsus LeUprolide Cardiac Trial · 35 trials list this drug (17 active) | — | — | Malignant Prostate Neoplasm,Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06631521Phase 1 · recruiting Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer · 35 trials list this drug (17 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06671548Phase 3 · recruiting Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids · 35 trials list this drug (17 active) | — | — | Uterine Corpus Leiomyoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06462014completed Description of Relugolix Use in Patients With Prostate Cancer Within the VHA · 35 trials list this drug (17 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04666129Phase 1 · completed Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer · 35 trials list this drug (17 active) | — | — | Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07069465early Phase 1 · completed Pilot Study: Androgen Deprivation Therapy Impact on PSMA-PET Sensitivity in Prostatectomy Staging · 35 trials list this drug (17 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03751124Phase 3 · completed Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids · 35 trials list this drug (17 active) | — | — | Uterine Corpus Leiomyoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03412890Phase 3 · completed LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids · 35 trials list this drug (17 active) | — | — | Uterine Corpus Leiomyoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06129851Phase 2 · not yet recruiting Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer · 35 trials list this drug (17 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03103087Phase 3 · completed LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids · 35 trials list this drug (17 active) | — | — | Uterine Corpus Leiomyoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03049735Phase 3 · completed LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids · 35 trials list this drug (17 active) | — | — | Uterine Corpus Leiomyoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03085095Phase 3 · completed A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer · 35 trials list this drug (17 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02655224Phase 3 · completed A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids · 35 trials list this drug (17 active) | — | — | Uterine Corpus Leiomyoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02655237Phase 3 · completed A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids · 35 trials list this drug (17 active) | — | — | Uterine Corpus Leiomyoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02141659Phase 1 · completed A Study of TAK-385 in Hormone Treatment-naïve Participants With Prostate Cancer · 35 trials list this drug (17 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02083185Phase 2 · completed A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer · 35 trials list this drug (17 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02135445Phase 2 · completed Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer · 35 trials list this drug (17 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02093390Phase 1 · completed A Phase 1 Study to Evaluate the Effects of Fluconazole and Atorvastatin on the Pharmacokinetics of TAK-385 in Healthy Subjects · 35 trials list this drug (17 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01452659Phase 2 · completed Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids · 35 trials list this drug (17 active) | — | — | Uterine Corpus Leiomyoma | 1 | Observed | clinicaltrials | graph → |